---
title: "Eli Lilly's Q1 Surge: Institutional Giants Anchor the Weight-Loss Thesis"
type: news
slug: eli-lilly-q1-earnings-institutional-holders
canonical_url: https://13finsight.com/news/eli-lilly-q1-earnings-institutional-holders
published_at: 2026-05-01T11:58:37.477Z
updated_at: 2026-05-01T11:58:39.157Z
author: Alex Rivera
author_title: Breaking News Editor
author_url: https://13finsight.com/authors/alex-rivera
word_count: 453
locale: en
source: 13F Insight
---

# Eli Lilly's Q1 Surge: Institutional Giants Anchor the Weight-Loss Thesis

> Eli Lilly's robust Q1 results and obesity drug success are backed by a deep institutional holder base, including the Lilly Endowment and BlackRock.

Eli Lilly's Obesity Franchise Drives Q1 Outperformance Eli Lilly & Co. (LLY) reported first-quarter results that highlighted the accelerating momentum of its GLP-1 franchise. As Mounjaro and Zepbound continue to capture significant market share in the obesity and diabetes categories, the company's valuation has reached historic highs. However, a look beneath the surface reveals an institutional holder base that is as much about long-term stability as it is about current growth. The 13F Insight database tracks 4,559 institutional holders for Eli Lilly, representing a diverse mix of legacy foundations, passive indexers, and high-conviction active managers. This deep pool of capital provides a structural advantage for Lilly as it navigates the complex manufacturing and regulatory hurdles associated with its blockbusters. Foundation and Finance: The Unique LLY Holder Base Unlike many of its big-tech peers, Eli Lilly's holder table is topped by a unique entity: the Lilly Endowment Inc., which holds a massive $84.5 billion stake. This philanthropic giant provides a level of shareholder stability that is rare in the S&P 500, serving as a permanent anchor for the company's strategic direction. Beyond the endowment, the institutional presence remains heavy. BlackRock, Inc. holds a $71.8 billion position, while PNC Financial Services Group ($54.9 billion) and State Street Corp ($38 billion) also maintain significant exposure. This combination of "patient capital" and institutional scale creates a formidable barrier to entry for competitors. Active Conviction: 16 Top-Tier Managers in the Mix While passive flows are a factor for any mega-cap, Lilly's "active" holder count is particularly high, with 16 such managers in the top 20. This includes firms like FMR LLC (Fidelity) with $27.6 billion. The presence of these active managers, who have the flexibility to reallocate capital based on clinical data and supply-chain execution, is a testament to the fundamental strength of the Lilly thesis. Our data also flags the presence of an "active whale" in the LLY holder set. This indicates that at least one major manager is holding a position that is significantly larger than their peer group average, signaling an outlier level of conviction in the obesity drug pipeline's long-term trajectory. Conclusion: Monitoring the Pipeline and the Portfolios The story of Eli Lilly in 2026 is one of execution and scale. As the company expands its manufacturing footprint to meet unprecedented demand, the institutional holder base will be the primary source of market signals. We will be closely watching the next round of 13F filings for any "rebalancing" activity among the top 10 active holders, particularly as valuations remain at elevated levels. Track the full list of Eli Lilly institutional holders and see real-time data on ownership shifts. For more on the managers driving this sector, explore our research on BlackRock and State Street.

---

Source: 13F Insight — https://13finsight.com/news/eli-lilly-q1-earnings-institutional-holders
Author: Alex Rivera — https://13finsight.com/authors/alex-rivera
Last updated: 2026-05-01T11:58:39.157Z